Related Experiment Video
Updated: Aug 18, 2026

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells
Published on: June 5, 2020
Hepatitis B virus and hepatitis C virus infections in children
Pier-Angelo Tovo1, Luisella Lazier, Antonia Versace
1Department of Pediatrics, University of Turin, Turin, Italy. pierangelo.tovo@unito.it
Insights
Hepatitis B vaccine coverage needs improvement globally. While hepatitis B and C infections are often mild in children, early treatment is crucial due to long-term concerns, though optimal therapies require further study.
Area of Science:
- Pediatric Infectious Diseases
- Hepatology
- Vaccinology
Background:
- Hepatitis B and C virus infections pose long-term health risks, even if asymptomatic in childhood.
- Understanding transmission, natural history, and treatment efficacy in children is critical for public health.
Purpose of the Study:
- To review recent data on hepatitis B vaccination efficacy, duration, and coverage.
- To analyze hepatitis B and C virus transmission, natural history, and treatment in pediatric populations.
- To assess the efficacy and safety of current therapies for childhood hepatitis B and C.
Main Methods:
- Systematic review of recent scientific literature.
- Analysis of data on vaccine coverage, viral mutants, and transmission dynamics.
- Evaluation of clinical trial outcomes for antiviral therapies in children.
Main Results:
- Hepatitis B vaccine coverage is insufficient in many regions; viral mutants may impact efficacy.
- No effective interventions prevent vertical hepatitis C virus transmission.
- Hepatitis B and C infections progress slower in children than adults, with lower spontaneous clearance rates for hepatitis B.
- Interferon-based therapies show efficacy and safety in children, but optimal treatment remains undefined.
Conclusions:
- Long-term persistence of hepatitis B immunity is uncertain in low-endemicity areas.
- Routine hepatitis C screening during pregnancy is not recommended due to lack of prophylaxis.
- Early treatment for childhood hepatitis B and C is advised, preferably within clinical trials to optimize efficacy and tolerance.
Purpose Of Review:
To analyse the most relevant recent information on efficacy, duration and coverage of anti-hepatitis B virus vaccination; correlates of mother-to-child hepatitis C virus transmission; the natural history and outcomes of hepatitis B and C virus infections in children; the efficacy and safety of specific therapies.
Recent Findings:
Insufficient hepatitis B virus vaccine coverage and incomplete or delayed vaccine cycles need improvement in many countries. Hepatitis B virus mutants may explain some fulminant hepatitis in perinatally infected infants and vaccine failures. No interventions to prevent vertical hepatitis C virus transmission have been identified. Spontaneous clearance of hepatitis B is lower in children than in adults, while the rates appear to be similar for hepatitis C. The disease progression is slower for both infections in childhood. Several studies support the efficacy and safety of interferons and lamivudine in chronic hepatitis B or of interferons and ribavirin in chronic hepatitis C in children, but the optimal therapy remains unclear.
Summary:
There are doubts as to the long-term persistence of anti-hepatitis B immunization in low-endemicity areas. Routine hepatitis C virus testing in pregnancy is not recommended as there are no available prophylactic measures. Although hepatitis B and C virus infections are usually asymptomatic or with mild manifestations in childhood, concerns around their long-term clinical impact suggest the need for early treatment. Children should preferably be treated in the context of targeted trials for a better understanding of the efficacy and tolerance of drugs currently used in adults.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Cytomegalovirus Disease
Poliomyelitis
Respiratory Syncytial Virus Disease
Genital Herpes

